Biote (BTMD) Q1 2026 Earnings Call Transcript

Biote reported Q1 revenue of $44.9 million, down 8.3%, as a voluntary hormone pellet recall cut revenue by an estimated $1.7 million and added about $1.5 million of incremental costs. Gross margin compressed to 68.9% from 74.3%, adjusted EBITDA fell to $8.7 million, and net income dropped to $2.7 million from $15.8 million. Management reaffirmed 2026 guidance for revenue above $190 million and adjusted EBITDA above $38 million, but said second-quarter margins and procedure revenue remain pressured by supply constraints and third-party pellet sourcing.

Analysis

The market should treat this as a temporary operating-disruption event, not a thesis break, but the second-order damage is more than just one soft quarter: the recall impaired field productivity, slowed new-clinic monetization, and likely pushed out the conversion curve on the recently expanded sales force. That means the real earnings risk is not the reported Q1 miss; it is the lag between inventory normalization and when the newer reps and trained practitioners start generating meaningful procedures, which the company itself suggests is more of a second-half story.

The key competitive dynamic is that supply reliability becomes the product. In a fragmented practitioner-led channel, clinics remember who could fulfill cases when inventory was tight, so even a short disruption can create share shifts toward alternative modalities or rival compounding pharmacies that are not visible in the reported numbers. The fact that gross margin is being supported by third-party supply today while vertical production catches up also implies near-term dilution in the very operating leverage investors are underwriting for the back half.

The contrarian angle is that guidance may be achievable even if execution is merely average, because the setup is now much more about normalization than expansion. If management truly rebuilds safety stock within weeks, the combination of a larger rep base and a full training pipeline can produce a sharper-than-expected rebound in procedures into late Q3/Q4; however, if inventory remains allocated longer than expected, the company risks converting a temporary recall into a durability problem for practitioner trust. The market is likely underestimating how quickly sentiment can reverse once daily case volumes recover, but it is also underpricing the chance that the reimbursement of lost volume is only partial because some patients never reschedule.

Key Decisions for Investors

• Trade idea: buy BTMD only on weakness after confirmation of inventory normalization, not ahead of it; use a 6-10 week horizon and size for event risk because the stock is still exposed to another quarter of margin compression from third-party pellet mix.
• Options: consider a small BTMD call spread expiring 4-6 months out to express a second-half recovery view while capping downside if recall-related slippage persists into Q3.
• Pair trade: long BTMD / short a basket of higher-duration healthcare names that lack a near-term catalyst; if procedures re-accelerate, BTMD should outperform on operating leverage, but only after the supply issue clears.
• If already long, hedge with a near-dated put spread into the next update; the tail risk is not demand collapse but another delay in safety-stock rebuild that would force guidance fatigue and multiple compression.
• Avoid chasing the stock until management shows two consecutive months of normalized case flow; the first credible buy signal is operational, not financial, and likely arrives before the next earnings release.